Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function

<p>Abstract</p> <p>Type 1A diabetes mellitus (T1ADM) is a progressive autoimmune disease mediated by T lymphocytes with destruction of beta cells. Up to now, we do not have precise methods to assess the beta cell mass, "<it>in vivo</it>" or "<it>ex-...

Full description

Bibliographic Details
Main Authors: Dib Sergio A, Gomes Marilia B
Format: Article
Language:English
Published: BMC 2009-12-01
Series:Diabetology & Metabolic Syndrome
Online Access:http://www.dmsjournal.com/content/1/1/25
id doaj-00df1b8fd126464f88443d0598cb53ed
record_format Article
spelling doaj-00df1b8fd126464f88443d0598cb53ed2020-11-24T21:55:48ZengBMCDiabetology & Metabolic Syndrome1758-59962009-12-01112510.1186/1758-5996-1-25Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell functionDib Sergio AGomes Marilia B<p>Abstract</p> <p>Type 1A diabetes mellitus (T1ADM) is a progressive autoimmune disease mediated by T lymphocytes with destruction of beta cells. Up to now, we do not have precise methods to assess the beta cell mass, "<it>in vivo</it>" or "<it>ex-vivo</it>". The studies about its genetic susceptibility show strong association with class II antigens of the HLA system (particularly DQ). Others genetics associations are weaker and depend on the population studied. A combination of precipitating events may occur at the beginning of the disease. There is a silent loss of immune-mediated beta cells mass which velocity has an inverse relation with the age, but it is influenced by genetic and metabolic factors. We can predict the development of the disease primarily through the determination of four biochemically islet auto antibodies against antigens like insulin, GAD65, IA2 and Znt8. Beta cell destruction is chronically progressive but at clinical diagnosis of the disease a reserve of these cells still functioning. The goal of secondary disease prevention is halt the autoimmune attack on beta cells by redirecting or dampening the immune system. It is remains one of the foremost therapeutic goals in the T1ADM. Glycemic intensive control and immunotherapeutic agents may preserve beta-cell function in newly diagnosed patients with T1ADM. It may be assessed through C-peptide values, which are important for glycemic stability and for the prevention of chronic complications of this disease. This article will summarize the etiopathogenesis mechanisms of this disease and the factors can influence on residual C-peptide and the strategies to it preservation.</p> http://www.dmsjournal.com/content/1/1/25
collection DOAJ
language English
format Article
sources DOAJ
author Dib Sergio A
Gomes Marilia B
spellingShingle Dib Sergio A
Gomes Marilia B
Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function
Diabetology & Metabolic Syndrome
author_facet Dib Sergio A
Gomes Marilia B
author_sort Dib Sergio A
title Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function
title_short Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function
title_full Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function
title_fullStr Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function
title_full_unstemmed Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function
title_sort etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual β cell function
publisher BMC
series Diabetology & Metabolic Syndrome
issn 1758-5996
publishDate 2009-12-01
description <p>Abstract</p> <p>Type 1A diabetes mellitus (T1ADM) is a progressive autoimmune disease mediated by T lymphocytes with destruction of beta cells. Up to now, we do not have precise methods to assess the beta cell mass, "<it>in vivo</it>" or "<it>ex-vivo</it>". The studies about its genetic susceptibility show strong association with class II antigens of the HLA system (particularly DQ). Others genetics associations are weaker and depend on the population studied. A combination of precipitating events may occur at the beginning of the disease. There is a silent loss of immune-mediated beta cells mass which velocity has an inverse relation with the age, but it is influenced by genetic and metabolic factors. We can predict the development of the disease primarily through the determination of four biochemically islet auto antibodies against antigens like insulin, GAD65, IA2 and Znt8. Beta cell destruction is chronically progressive but at clinical diagnosis of the disease a reserve of these cells still functioning. The goal of secondary disease prevention is halt the autoimmune attack on beta cells by redirecting or dampening the immune system. It is remains one of the foremost therapeutic goals in the T1ADM. Glycemic intensive control and immunotherapeutic agents may preserve beta-cell function in newly diagnosed patients with T1ADM. It may be assessed through C-peptide values, which are important for glycemic stability and for the prevention of chronic complications of this disease. This article will summarize the etiopathogenesis mechanisms of this disease and the factors can influence on residual C-peptide and the strategies to it preservation.</p>
url http://www.dmsjournal.com/content/1/1/25
work_keys_str_mv AT dibsergioa etiopathogenesisoftype1diabetesmellitusprognosticfactorsfortheevolutionofresidualbcellfunction
AT gomesmariliab etiopathogenesisoftype1diabetesmellitusprognosticfactorsfortheevolutionofresidualbcellfunction
_version_ 1725861243082768384